Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

Gene Therapy

Volumn 7, Issue 10, 2000, Pages 859-866

  Rampling, R ^a   Cruickshank, G ^b   Papanastassiou, V ^c   Nicoll, J ^d   Hadley, D ^c   Brennan, D ^c   Petty, R ^c   MacLean, A ^d   Harland, J ^d   McKie, E ^d   Mabbs, R ^d   Brown, M ^d  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clinical trial; Glioma therapy; HSV1716

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; ENCEPHALITIS; FEMALE; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN TISSUE; MALE; NEUROTOXICITY; PRIORITY JOURNAL; VIRUS ACTIVATION; VIRUS REPLICATION;

HERPES; SIMPLEXVIRUS;

EID: 12944272092     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301184     Document Type: Article

References (34)

1. Rampling R. Modern aspects of radiation therapy for glial tumours of the brain. Forum 1998; 8: 289-301.
2. Rampling R. Chemotherapy. Determining the appropriate treatment. In: Hopkins A, Davies EH (eds) Improving Care for Patients with Malignant Glioma. Royal College of Physicians: London, 1997, pp 63-74.
3. Rajan B. et al. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 1994; 30A: 1809-1815.
4. Gutin P, Leibel S. Stereotaxic interstitial irradiation of malignant brain tumours. Neurol Clin 1985; 3: 883-893.
5. Mbidde EK et al. High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 1988; 58: 779-782.
6. Lucas GL et al. Treatment results of stereotactic interstitial brachytherapy for primary and metastatic brain tumours. Int J Radiat Oncol Biol Phys 1991; 21: 715-721.
7. MacLean AR et al. Herpes simplex virus type 1 variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72: 631-639.
8. Dolan A, McKie E, MacLean A, McGeoch D. Status of ICP34.5 gene in herpes simplex virus type 1 strain 17. J Gen Virol 1992; 73: 971-973.
9. Ackermann M et al. Identification by antibody to a synthetic peptide of a protein specified by a diploid gene located in the terminal repeats of the L component of the herpes simplex virus genome. J Virol 1986; 58: 843-850.
10. Brown SM et al. Cell type and cell state determine differential in vitro growth of non virulent ICP34.5 negative herpes simplex virus. J Gen Virol 1994; 75: 2367-2377.
11. Randazzo RB et al. Treatment of experimental intracranial murine melanoma with neuroattenuated herpes simplex virus type 1 mutant. Virology 1995; 211; 94-101.
12. Kesari S et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995; 73: 636-648.
13. Kucharczuk J et al. Use of a 'replication-restricted' herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57: 466-471.
14. McKie EA, Brown SM, MacLean A, Graham DI. Histopathological responses in the CNS following innoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV1): relevence for gene and cancer therapy. Neuropath Appl Neurobiol 1998; 24: 367-372.
15. McKie EA et al. Selective in vitro killing of primary CNS tumours using herpes simplex virus type1 (HSV-1), ICP34.5 null mutants - a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-752.
16. Brown SM, MacLean A, McKie E, Harland J. The herpes simplex virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63 amino acid domain conserved in ICP34.5, MyD116 and GADD34. J Virol 1997; 71: 9442-9449.
17. Chou J, Roizman B. The gamma 34.5 gene of herpes simplex virus type 1 precludes neuroblastoma cells from triggering total shut off of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Nat Acad Sci USA 1992; 89: 3266-3270.
18. Chou J, Roitzman B. HSV1 34.5 gene function which blocks the host response to infection maps in the homologous domain of genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci USA 1994; 91: 5247-5251.
19. He B et al. The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma 34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J Virol 1996; 70: 84-90.
20. Mulvey M, Poppers J, Ladd J, Mohr I. A herpes virus ribosome associated RNA binding protein confers a growth advantage upon mutants deficient in GADD 34 related function. J Virol 1999; 73: 3375-3385.
21. Valyi-Nagi T et al. The HSV-1 strain 17+gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 1994; 75: 2059-2063.
22. Harland J, Brown SM. HSV growth preparation and assay. In: Brown SM, MacLean AR (eds). Herpes Simplex Virus Protocols. Methods in Molecular Medicine. Humana Press: 1997.
23. Arbuck SG. Workshop on phase 1 study design Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 1996. Ann Oncol 1996; 7: 567-573.
24. Steward WS. Phase 1 studies-alternative endpoints: when is toxicity not appropriate? In 9th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1996.
25. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401: 517-518.
26. Cruickshank GS. The use of SPECT in the analysis of brain tumours, In: Duncan R (ed). SPECT Imaging of the Brain. Kluwer Academic Publishers: Dordrecht, 1997, pp 161-178.
27. Macdonald DR, Terrance LC, Cascino S, Schold C. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
28. Kesari S et al. Selective vulnerability of mouse CNS neurons to latent infection with neuroattenuated HSV1. J Neurosci 1996; 16: 5644-5653.
29. Kesari S et al. A neuroattenuated ICP34.5-deficient herpes simplex type 1 replicates in ependymal cells of the murine central nervous system. J Gen Virol 1998; 79: 525-536.
30. Lasner TM et al. Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J Neurovirol 1998; 3: 100-105.
31. Chambers R et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumours in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-1415.
32. Markert JM et al. Initial report of phase 1 trial of genetically-engineered HSV-1 in patients with malignant glioma. In: 23rd International Herpesvirus Workshop. York, 1998.
33. Brown SM, Ritchie DA, Subak-Sharpe JH. Genetic studies with Herpes Simplex virus type 1. The isolation of temperature sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. J Gen Virol 1973; 18: 329-346.
34. Cone RW et al. Extended duration of Herpes Simplex Virus DNA in genital lesions detected by polymerase chain reaction. J Infect Dis 1991; 164: 757.